These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 8691441)

  • 1. Topographical amino acid substitution in position 10 of glucagon leads to antagonists/partial agonists with greater binding differences.
    Azizeh BY; Shenderovich MD; Trivedi D; Li G; Sturm NS; Hruby VJ
    J Med Chem; 1996 Jun; 39(13):2449-55. PubMed ID: 8691441
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of phenylalanine at position 6 in glucagon's mechanism of biological action: multiple replacement analogues of glucagon.
    Azizeh BY; Ahn JM; Caspari R; Shenderovich MD; Trivedi D; Hruby VJ
    J Med Chem; 1997 Aug; 40(16):2555-62. PubMed ID: 9258362
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low level cyclic adenosine 3',5'-monophosphate accumulation analysis of [des-His1, des- Phe6, Glu9] glucagon-NH2 identifies glucagon antagonists from weak partial agonists/antagonists.
    Van Tine BA; Azizeh BY; Trivedi D; Phelps JR; Houslay MD; Johnson DG; Hruby VJ
    Endocrinology; 1996 Aug; 137(8):3316-22. PubMed ID: 8754757
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pure glucagon antagonists: biological activities and cAMP accumulation using phosphodiesterase inhibitors.
    Azizeh BY; Van Tine BA; Trivedi D; Hruby VJ
    Peptides; 1997; 18(5):633-41. PubMed ID: 9213355
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthetic linear and cyclic glucagon antagonists.
    Dharanipragada R; Trivedi D; Bannister A; Siegel M; Tourwe D; Mollova N; Schram K; Hruby VJ
    Int J Pept Protein Res; 1993 Jul; 42(1):68-77. PubMed ID: 8396562
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structure-function studies on positions 17, 18, and 21 replacement analogues of glucagon: the importance of charged residues and salt bridges in glucagon biological activity.
    Sturm NS; Lin Y; Burley SK; Krstenansky JL; Ahn JM; Azizeh BY; Trivedi D; Hruby VJ
    J Med Chem; 1998 Jul; 41(15):2693-700. PubMed ID: 9667960
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of histidine-1 in glucagon action.
    Unson CG; Macdonald D; Merrifield RB
    Arch Biochem Biophys; 1993 Feb; 300(2):747-50. PubMed ID: 8382034
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthetic glucagon antagonists and partial agonists.
    Zechel C; Trivedi D; Hruby VJ
    Int J Pept Protein Res; 1991 Aug; 38(2):131-8. PubMed ID: 1664420
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel diastereomeric opioid tetrapeptides exhibit differing pharmacological activity profiles.
    Ioja E; Tourwé D; Kertész I; Tóth G; Borsodi A; Benyhe S
    Brain Res Bull; 2007 Sep; 74(1-3):119-29. PubMed ID: 17683797
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activation of the hepatic glycine cleavage enzyme system by glucagon and glucagon-related peptides.
    Mabrouk GM; Brosnan JT
    Can J Physiol Pharmacol; 1997 Sep; 75(9):1096-100. PubMed ID: 9365819
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glucagon antagonists: contribution to binding and activity of the amino-terminal sequence 1-5, position 12, and the putative alpha-helical segment 19-27.
    Unson CG; Gurzenda EM; Iwasa K; Merrifield RB
    J Biol Chem; 1989 Jan; 264(2):789-94. PubMed ID: 2536024
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthetic peptide antagonists of glucagon.
    Unson CG; Andreu D; Gurzenda EM; Merrifield RB
    Proc Natl Acad Sci U S A; 1987 Jun; 84(12):4083-7. PubMed ID: 3035568
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modifications to the N-terminus but not the C-terminus of calcitonin gene-related peptide(8-37) produce antagonists with increased affinity.
    Smith DD; Saha S; Fang G; Schaffert C; Waugh DJ; Zeng W; Toth G; Hulce M; Abel PW
    J Med Chem; 2003 Jun; 46(12):2427-35. PubMed ID: 12773046
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Divergent structural requirements exist for calcitonin receptor binding specificity and adenylate cyclase activation.
    Houssami S; Findlay DM; Brady CL; Martin TJ; Epand RM; Moore EE; Murayama E; Tamura T; Orlowski RC; Sexton PM
    Mol Pharmacol; 1995 Apr; 47(4):798-809. PubMed ID: 7723741
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human growth hormone-releasing hormone hGHRH(1-29)-NH2: systematic structure-activity relationship studies.
    Cervini LA; Donaldson CJ; Koerber SC; Vale WW; Rivier JE
    J Med Chem; 1998 Feb; 41(5):717-27. PubMed ID: 9513600
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of the substitution of Phe4 in the opioid peptide [D-Ala8]dynorphin A-(1-11)NH2.
    Vig BS; Zheng MQ; Murray TF; Aldrich JV
    J Med Chem; 2003 Sep; 46(19):4002-8. PubMed ID: 12954053
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Receptor binding and adenylate cyclase activities of glucagon analogues modified in the N-terminal region.
    McKee RL; Pelton JT; Trivedi D; Johnson DG; Coy DH; Sueiras-Diaz J; Hruby VJ
    Biochemistry; 1986 Apr; 25(7):1650-6. PubMed ID: 3011069
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optically active aromatic amino acids. Part VI. Synthesis and properties of (Leu5)-enkephalin analogues containing O-methyl-L-tyrosine1 with ring substitution at position 3'.
    Arnold ZS; Schiller PW
    J Pept Sci; 2000 Jun; 6(6):280-9. PubMed ID: 10912908
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design of oxytocin antagonists, which are more selective than atosiban.
    Manning M; Stoev S; Cheng LL; Wo NC; Chan WY
    J Pept Sci; 2001 Sep; 7(9):449-65. PubMed ID: 11587184
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of an essential serine residue in glucagon: implication for an active site triad.
    Unson CG; Merrifield RB
    Proc Natl Acad Sci U S A; 1994 Jan; 91(2):454-8. PubMed ID: 8290548
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.